University at Buffalo - The State University of New York
Skip to Content
 Office of Cancer Clinical Proteomics Research |

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

Proteogenomics Research

Preoteogenomics Research – On the Frontier of Precision Medicine

Learn about cancer genomics, how it is being integrated with proteomics (termed proteogenomics), and how proteogenomics is anticipated to improve precision medicine.

Korea University Joins the International Efforts in Clinical Proteogenomics Cancer Research

The National Cancer Institute's (NCI) Office of Cancer Clinical Proteomics Research, part of the National Institutes of Health, and Korea University (KU) located in The Republic of Korea have signed a Memorandum of Understanding (MOU) in clinical proteogenomics cancer research. The MOU between...


Rodriguez Recognized as Recipient of the MSSS AACC Chair’s Inspirational Award

Dr. Henry Rodriguez, director of the Office of Cancer Clinical Proteomics Research, has been recognized as the recipient of the Chair’s Inspirational Award by the Mass Spectrometry and Separation Sciences for Laboratory Medicine Division (MSSS), American Association for Clinical Chemistry (AACC...


Leaderboard Now Open: CPTAC’s DREAM Proteogenomics Computational Challenge

The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce the opening of the leaderboard to its Proteogenomics Computational DREAM Challenge. The leadership board remains open for submissions during September 25, 2017 through October 8, 2017,...


NCI Releases Video: Proteogenomics Research - On the Frontier of Precision Medicine

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of an educational video titled “Proteogenomics Research: On the Frontier of Precision Medicine."  Launched at the HUPO2017 Global...


Oral Squamous Cell Carcinoma Mutational Profile in Taiwanese Population

Oral squamous cell carcinoma (OSCC) is a major oral cancer subtype that is the fourth most common cancer affecting Taiwanese men. Despite known risk behaviors such as cigarette smoking, alcohol drinking, and betel nut chewing often indulged by Taiwanese men, the genetic contribution to the...


47th Vice President of the United States Joseph R. Biden, Jr. to deliver keynote address at HUPO2017 Global Leadership Gala Dinner

The Human Proteome Organization (HUPO) and Prof Steve Pennington, UCD, chair of the organizing committee of HUPO2017 (the 16th HUPO World...


CPTAC Collaborates with Molecular & Cellular Proteomics to Address Reproducibility in Targeted Assay Development

The journal Molecular & Cellular Proteomics (MCP), in collaboration with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announce new guidelines and requirements for papers describing the development...


CPTAC Team Releases Targeted Proteomic Assays for Ovarian Cancer

Pacific Northwest National Laboratory (PNNL) investigators in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), announces the public release of 98 targeted mass spectrometry-based assays for ovarian cancer research studies.  Chosen based on...


NCI and FDA to Study Cancer Proteogenomics Together

The National Cancer Institute (NCI) Office of Cancer Clinical Proteomics Research (OCCPR), part of the National Institutes of Health, and the U.S. Food and Drug Administration (FDA) has signed a Memorandum of Understanding (MOU) in proteogenomic regulatory science.  This will allow the agencies...


Announcing the Launch of CPTAC’s Proteogenomics DREAM Challenge

This week, we are excited to announce the launch of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Proteogenomics Computational DREAM Challenge.  The aim of this Challenge is to encourage the generation of computational methods for extracting information...


Pages